Eporgen Venture SpA, an Italian early stage venture capital fund with a diversified investor base, has logged the first major transaction of its portfolio, the licensing of a therapeutic cancer vaccine program, GX301, from Genovax srl to Mediolanum Farmaceutici SpA.